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A systematic review (SR) can provide rigorous and complete
evidence to support decision makers who consider both the
effectiveness and cost-effectiveness of health interventions. A
dramatic increase in published health economic (HE) studies,
more specifically cost and cost-effectiveness studies, has resulted
in the consequent proliferation of systematic reviews with cost
and cost-effectiveness outcomes (SR-CCEO).1,2 First, such reviews
help to indentify strenghts and weaknesses in HE studies,
modelling methodologies, and data for modelling inputs. Second,
SR-CCEOs may be informative for decisionmakers in resource
allocation decisions for health interventions, especially in coun-
tries with limited capacity for health technology assessment
(HTA). For the purpose of this article, cost studies are defined as
studies analyzing the costs of healthcare interventions, including
cost descriptions and cost-of-illness (economic burden of disease)
studies. By cost-effectivenessstudies we mean full economic eval-
uations, including cost-minimization, cost-effectiveness analysis,
cost-utility analysis, cost-benefit analysis, and cost-consequence
analysis. Sometimes cost studies might be based on an explicit
comparison of alternatives.
However, it is challenging to appropriately interpret SR-CCEOs
owing to their heterogeneity in applied methods and reporting,
and furthermore, owing to variability in clinical and health set-
tings in the original studies they include. Methodologic guidance
and checklists that improve the quality of SRs on clinical evidence
or decrease risk of bias in their interpretation or synthesis3-6 have
limited applicability for SR-CCEOs. There is little specific meth-
odologic guidance for SR-CCEOs.7-11 Although Chapter 20 of the
Cochrane Handbook for Systematic Reviews of Interventions of the
Cochrane Collaboration12 and 3 articles related to informing clinical
practice guidelines7-9 provide guidance, their recommendations
do not focus on evaluating the quality of conduct or the risk of bias
in SR-CCEOs. A critical analysis of guidelines on conducting and
reporting SR-CCEOs identified multiple disagreements in these
recommendations, suggesting that a standardized approach to
conducting SR-CCEOs is needed.13
Making universal recommendations for SR-CCEOs is difficult
because they differ in several important aspects, in particular,
with regard to their search and inclusion criteria, such as the
types of studies included (trial or model-based, cost, or1098-3015/$36.00 - see front matter Copyright ª 2021, ISPOR–The Professional Socost-effectiveness), or in reporting solely economic characteris-
tics or economic data alongside clinical outcomes. They also have
different objectives (eg, to assess variability in outcomes and
synthesize the findings) to identify the evidence gaps, or to
assess the methods used.
Overall, SR-CCEO reliability and usefulness will improve with
good practice guidance for SR-CCEOs with different objectives.
Thus, ISPOR (The Professional Society for Health Economics and
Outcomes Research) established a global, multistakeholder,
multidisciplinary expert task force to address this need (Appendix
1 in Supplemental Materials found at https://doi.org/10.1016/j.
jval.2021.01.002).
Although general recommendations on conducting SR-CCEOs
are provided, the main goal is guidance on critical appraisal of
SR-CCEOs regarding their quality and risk of bias. This report,
which includes the ISPOR Criteria for Cost(-Effectiveness) Re-
view Outcomes (CiCERO) Checklist, will assist researchers, pro-
ducers of health technologies, and evidence users (decision
makers/commissioners). The task force categorized the recom-
mendations according to the 6 stages of conducting an SR-CCEO
(Table 1).
Stage 1. Planning and Development
Each SR should be based on a comprehensive predefined
protocol. It is a preferred practice to make the protocol of SR
publicly available to prevent duplication of ongoing reviews, in-
crease reproducibility of the research, and to avoid selective
reporting. This can be achieved by registering the protocol with
either immediate or delayed open access, (International prospec-
tive register of systematic reviews PROSPERO, the Centre for Open
Science, or another independent online database), or by publish-
ing it. Any deviations from this protocol should be included in the
final report or publication. Independent of protocol availability,
each review should have clearly stated objectives consistent with
its reported results and conclusions, such as to synthesize the
outcomes or to assess the methods.
It is routine practice to develop eligibility criteria around the
PICO (population, intervention, comparator, and outcome) mne-
monic in clinical reviews14 or reviews of full economic evalua-
tions.8 However, PICO or its derivatives are not fully applicable for
methodologic (eg, reviews appraising the design of economicciety for Health Economics and Outcomes Research. Published by Elsevier Inc.
Table 1. Overview of major quality and risk of bias criteria for systematic reviews of cost and cost-effectiveness outcomes
N Title of the stage Topics covered
Stage 1 Planning and development Clear objective
Predefined and available protocol
Protocol deviations
Stage 2 Search for evidence Update or novel systematic review




Use of supplementary materials
Use of grey literature
Stage 3 Study selection and eligibility Process of study selection
Eligibility criteria used
Stage 4 Critical appraisal of included studies Tools to appraise the included studies
Process of appraisal
Stage 5 Data extraction and synthesis Process of data-extraction
Assessment of heterogeneity
Methods of synthesis
Assessment of publication bias
Stage 6 Presentation and reporting Reporting of included studies
Reporting of the synthesis
464 VALUE IN HEALTH APRIL 2021models) or cost reviews (eg, cost of illness) in which the
“comparator” or “intervention” component may be absent.
Depending on the objectives of the SR-CCEO, its design can be
focused on:
 model-based studies: for example, reviews assessing quality of
models and reviews of studies using a life-time time horizon;
 empirical health economic studies: for example, reviews
assessing treatment costs and reviews of cost-effectiveness
studies using a short time horizon (The task force uses the
term empirical studies for single study-based economic evalua-
tions, such as randomized and nonrandomized trial-based
economic evaluations and also observational studies [single
arm, multiple arm, real-world data] that are used as a basis for
cost-effectiveness analyses, often called piggy-back studies.
Empirical studies are contrasted with modeling studies,
explicitly synthesizing data using various sources);
 or both, for example, reviews with broad perspectives and
multiple time horizons.
Because SR-CCEOs are often used to inform decision makers,
additional framing definitions are essential: time horizon and
study perspective. These elements define which methods should
be used for the literature search and synthesis.Stage 2. Search for Evidence
A review cannot be considered systematic if it is based on
evidence identified through a nontargeted, unsound, incomplete,
or nonreproducible search.15 The quality of the search depends on
the experience of the person or group who developed the
search.16,17 Approaches to improving the quality of the search
include involving information specialists or library scientists insearch strategy development and using the peer-review electronic
search strategies guidelines.17,18
If a SR-CCEO is performed to update existing reviews, reusing
the same search strategies may be appropriate. However, the
quality of the initial search strategy should be re-evaluated. If a
review uses search strategies from existing reviews to answer
amended research questions, reviewers need to ensure that the
adaptations in the objectives are reflected in the search strategy.
Conducting a SR is time-consuming. For clinical reviews it
takes an average of 17 months from the registered project start to
the publication date.19,20 We expect that SR-CCEOs will have
similar timelines: adding search words related to costs to the
search line used in a clinical SR will result in less hits, but a more
complicated complementary search for grey literature will often
be needed.
Cochrane requires the search date to be within 12 months of
the publication date.12 This requirement is appropriate for SR-
CCEOs summarizing outcomes. Therefore, a SR-CCEO should be
conducted in the shortest time possible that does not compromise
quality and comprehensiveness or should be updated before
publication. Approaches that can decrease the review’s time
requirement include narrowing the SR-CCEO’s objective or setting
search restrictions if it is feasible and defensible. However, the
task force believes that time duration may be less crucial for
methodologic than other reviews, given their objectives.
Selection of Literature Databases
Which sources to include in the systematic search should be
justified primarily by the review’s objectives, and it is unlikely that
searching a single database will identify all relevant literature.21
There are different viewpoints on the best databases to
search.7,22,23 However, an empirical study concluded that a search
in Embase, HTA-journal database, MEDLINE/PubMed, and Scopus
enabled identification of almost all the references in a SR-CCEO.23
ISPOR REPORT 465To minimize the risk of missing relevant studies, we recom-
mend starting with the most commonly used international data-
bases for cost and cost-effectiveness studies. A review of cost-
effectiveness reviews (ie, an umbrella review) showed that the
most commonly used resources (in order) were: MEDLINE, NHS
EED (updated up to 2015), checking reference lists, Embase, and
HTA report databases22 (see Appendix B in Supplemental Mate-
rials found at https://doi.org/10.1016/j.jval.2021.01.002 for data-
bases reflecting specific health topics and for SR-CCEOs with a
regional focus).
Including multiple databases will likely identify more relevant
studies, but it comes at the cost of additional records that need
screening.24,25 Although we recommend searching at least 3 da-
tabases, if the reviewers chose not to, their decision should be
well-justified and confirmed with evidence.
Developing and Reporting a Search Strategy
The search strategy should be comprehensive enough to
identify all relevant literature and reproducible, therefore,
described in detail. Existing search filters can be used to identify
cost and cost-effectiveness studies.26,22 In addition, recommen-
dations on search term and filter selection (including Boolean
operators), as well as considerations on sensitivity to specificity
trade-offs and SR-CCEO objectives, are useful.7,12
Review authors should consider whether applying restrictions
in the search (date of publication, study design, publication
format, language, age of the subjects) might limit identification of
all relevant literature. For example, if the review searched both
clinical and cost-effectiveness studies and limits the search to
RCTs, it misses possibly relevant model-based research.
Reviewers should consider that empirical studies measuring
both clinical and cost outcomes are likely to report clinical and
cost/cost-effectiveness results in separate publications. Therefore,
for reviews with both clinical and economic studies, separate
searching for articles reporting on either outcome may be pref-
erable to increase the search results’ comprehensiveness.
Supplemental Searches
Even comprehensive search strategies may miss relevant
studies, as approximately 4% of included studies were missed by
database searches.23 In addition to database searches, other stra-
tegies to identify published literature include “snowballing”
techniques (searching the bibliographies of all included studies),
personal knowledge of existing studies, citation tracking, or by
contacting experts in the field.27 This means that the process of
identifying relevant literature should include supplemental
searches28 using at least 1-step back citation tracking of included
studies.
Searching for Grey Literature
Searching grey literature is challenging because the results are
dependent on when the search is conducted, and therefore,
potentially nonreproducible. Grey literature refers to research that
is either unpublished or has been published outside of the tradi-
tional commercial or academic publishing and distribution chan-
nels. Examples of grey literature include government reports,
policy statements, and issues articles. However, grey literature
may be particularly important to SR-CCEOs as one way to address
publication bias. Thus, if a search of grey literature is not per-
formed, it should be clearly justified.
We recommend including grey literature and to follow rec-
ommendations on grey literature searches.29 A supplementary
search on HTA is especially important for SR-CCEOs because
relevant reports may not be in HTA databases (see sources inAppendix B, sections 2 and 3 in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2021.01.002). Furthermore, the au-
thors may want to explore platforms that collect and aggregate
grey literature regarding specific topics, such as the Program for
Monitoring Emerging Diseases (ProMED) of the International So-
ciety for Infectious Diseases (https://promedmail.org/about-
promed/).
As a general rule, we do not recommend that abstracts of
conference proceedings be included in a search, even if technically
possible. Scientific conference abstracts in SR-CCEOs could in-
crease the risk of bias because it has been shown that more than
half of such abstracts ultimately fail to publish their results after
peer review in full,30 and other abstracts (eg, the Society of
Medical Decision Making, Health Technology Assessment inter-
national conference abstracts) are not indexed in international
databases. Nevertheless, reviewers may include them if they make
a solid argument for inclusion, for instance, to identify such ab-
stracts for further follow-up for full-text publications.
Social networks (a social media website or other application
sharing information) may become additional sources of both
clinical and economic data for SR-CCEOs. Although unknown, the
risk of bias from these sources seems obvious. Reviewers should
not apply information derived from such networks without first
evaluating the risk of bias.Stage 3. Study Selection and Eligibility
The study selection process includes screening of titles, ab-
stracts, and full-text publications. Methods for study selection
should promote transparency and minimize bias. The trans-
parency in a SR-CCEO can be achieved by following SR reporting
guidelines, such as the PRISMA statement.6 There is unlikely to be
a “one-size-fits-all” approach, so when evaluating a SR-CCEO, it is
important to evaluate how the methodologic approach may
contribute to risk of bias.
For a SR-CCEO using the methods or outcomes from previously
published reviews, the risk of bias increases when the previous
reviews’ data analysis steps are applied. For example, the risk of
bias would be higher if not only the search results are applied, but
also full-text inclusion, due to the uncertainty in reliability of each
of the literature selection and analysis steps.
Process of Study Selection
There are a number of tools and methodologic recommenda-
tions on study selection in clinical SRs that are relevant for a SR-
CCEO. For example, AMSTAR-2 (A MeaSurement Tool to Assess
systematic Reviews) appraises the quality of conduct around study
selection,3 and Robson et al (2018) summarizes the key conclu-
sions of a SR related to study selection methods.31 The common
recommendation to minimize the risk of excluding a relevant
study or including an irrelevant study, is to perform each step of
the study selection process, ideally independently, in duplicate,
with conflicts resolved through discussion or by a third party
while a combination of both is to be preferred.
One approach to address the risk of bias in literature selection
if resources are limited, is to be more liberal in reviewing titles or
abstracts for inclusion by a single reviewer and then at the full-
text review stage, ensure that there is duplicate reviewing and
stringent criteria application. This should mitigate any issues with
a single reviewer and balance the risk of overinclusion (which
comes with more research costs) with the risk of excluding rele-
vant citations.30,31
Another strategy is using tools with machine learning capa-
bilities (eg, Abstrackr, DistillerSR, SWIFT-Active Screener, and
BOX 1. Study selection restrictions in eligibility criteria that represent trade-offs between internal validity and generalizability
 Restriction by publication date: If only including the last X years, the reviewer may actually increase generalizability to current
and future years due to changes in research methods, standard of care, or other parameters.
 Restriction by country/region: Restrictions by country/region are frequently motivated by healthcare system or cost
comparability, increasing internal validity for making statements about those settings (conditional on equally high quality of
studies). However, this limits generalizability to those countries/regions included and perhaps to very similar country/regions.
 Restriction by language: This restriction can increase validity, but limit generalizability (eg, restricting to English-language
publications while searching for US studies), or bias the outcomes (eg, restricting to English-language publications in studies with a
global perspective). The challenge of including studies published in many languages is that the reviewer needs to be able to read/
translate/interpret the text in each language, which may not be feasible. Although in some circumstances, Google Translate or other
tools can help to automate translations,31 the accuracy of these translations should be verified to avoid biases in interpretation.
466 VALUE IN HEALTH APRIL 2021RobotAnalyst). In particular, these tools can be used to duplicate
the manual selection. Although machine-learning tools decrease
screening time, the risk of bias in using such tools is currently
uncertain. The available evidence is limited, and their perfor-
mance is highly varied.32-34 If nonvalidated artificial intelligence
tools are used, their literature screening accuracy should be tested
on a sample and their use should be clearly reported.Restrictions in Eligibility Criteria
It is difficult to characterize how the use of greater restrictions
in study selection relates to the relevance and bias of a review’s
outcomes because such restrictions can increase or decrease these
measures. For example, in clinical reviews, restricting the inclu-
sion criteria to RCTs may increase the risk of bias with respect to
adverse event rates (underestimation), but decrease the risk of
bias in estimates of effectiveness.
For SR-CCEOs, there are a variety of relevant restrictions that
might be considered beyond study design. The combination of
these restrictions represents trade-offs between internal validity
and broader generalizability (Box 1). Furthermore, restrictions on
study perspective and cost methodologies (how and which costs
are included in the analyses) may increase or decrease bias rela-
tive to the review’s intended purpose.
Our experience suggests that applying restriction criteria dur-
ing the search or when screening titles and abstracts is efficient.
However, sometimes, full-text reading is unavoidable. If evidence
quality is used as an exclusion criterion, another approach to
assess the risk of bias would be to apply a scenario analysis where
excluded sources are included to see whether that changes the
conclusion.Stage 4. Critical Appraisal of Included Studies
HTA bodies demand transparency and sound methods in
original cost and cost-effectiveness studies to apply them in ap-
praisals. Logically, to reduce flaws in synthesizing the evidence, a
SR-CCEO should include a methodologic quality assessment of
included studies.
Although assessing the quality of included studies, reviewers
should provide a qualitative description and a critique of the ev-
idence base. Reviewers should be explicit about: (1) the existence
of and the type of biases that may exist in each study (eg, quality,
quality of reporting, and sponsorship in the study), and (2)
whether and how estimates were adjusted for transferability and
with what assumptions. To increase the consistency in assessment
of the methodologic quality of each included study, one of thestandard checklists (see below) is justified and should be used
over self-designed evaluation approaches.
Appropriate methodologic quality assessment for various kinds
of cost and cost-effectiveness publications depends on the type of
research conducted (eg, a trial-based study may need to focus
more on consideration of population generalizability). Thus,
assessment of quality in an empirical cost or cost-effectiveness
study should not be handled in the same way as the assessment
of a model.
There are a number of checklists developed to assess meth-
odologic quality or quality of reporting in included cost and cost-
effectiveness studies.9 The most commonly used are:
 British Medical Journal checklist35;
 Phillips checklist for model-based studies36;
 Quality of Cost-Effectiveness Studies checklist for model-based
evaluations37;
 Consensus on Health Economic Criteria (CHEC) for trial-based
studies38;
 Consolidated Health Economic Evaluation Reporting Standards
(CHEERS)39;
 Bias in Economic Evaluation (ECOBIAS) Checklist for trial- and
model-based studies40;
 Second Panel on Cost-Effectiveness checklist41;
 TRansparent Uncertainty ASsessmenT (TRUST) Tool for sys-
tematically identifying, assessing, and reporting uncertainties in
decision models42;
 Questionnaire to assess the relevance and credibility of a
modeling studies43
Most of these tools are comparable in their coverage of key
design characteristics. However, they differ in the extent to which
they are suitable for empirical or model-based studies or whether
their specific focus is on the quality of methods or on reporting.
TRUST deviates in this respect; it is focused on identifying,
assessing, and reporting uncertainty.42 In addition, the reviews of
modeling studies will benefit from assessment of data source
quality in the models.44
The selection of the right methodologic quality instrument will
be a trade-off between the research question and objectives of the
SR-CCEO, the available research capacity, the thoroughness of the
evaluation of quality, and the requirements of the project funder
or the target journal (if any). A comparative assessment of the
checklists is reported by Wijnen et al (2016).9 No single checklist
can be recommended, but a clear motivation must be given for use
in the SR-CCEO. To minimize systematic and nonsystematic errors,
at least, 2 reviewers should assess the quality of studies included
in a SR-CCEO independently.
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Performing Data Extraction
The same data extraction standards and expectations that
apply to SRs of clinical effectiveness should be applied to SR-
CCEOs. Data extraction by a single reviewer results in more er-
rors on average than does duplicated data extraction with the
observed relative difference in accuracy of 21.7%.45 Although
duplicated extraction is preferred from the accuracy viewpoint,
there is a trade-off between the accuracy and efforts required,30
especially because a SR-CCEO generally involves extracting a
broad range of target outcomes (ie, clinical, cost, and cost-
effectiveness outcomes), as well as data related to methodology.
If an independent duplicated extraction is not possible, reviewers
may consider performing a verification of study characteristics
and extracting outcome data independently in duplicate.46
Performing Data Synthesis
Considerations for synthesizing data depend on the purpose of
the review (eg, synthesizing the outcomes or reporting meth-
odologic issues).47 There is no consensus on the best way to
synthesize economic evidence. Possible approaches include
structured narrative synthesis (using descriptive methods instead
of statistical approaches),12 graphical synthesis (eg, cost-
effectiveness diagram, permutation matrix),48,49 hierarchical ma-
trix,50 or quantitative synthesis/meta-analysis (see “Meta-analysis
in SR-CCEO”).51,52 The stated order reflects the most applicable
synthesis approach (ie, the approach that can be used under any
circumstances to the least used synthesis based on lack of
applicability).
One of the main challenges in choosing the “best” synthesis
method for a particular SR-CCEO is matching the approach to
synthesis to the review’s scope and the observed variability among
the studies it identifies. This variability can be methodologic, clin-
ical, or health setting (administrative- or jurisdiction-related). It is
especially challenging to make a single recommendation on a
synthesis approach because SR-CCEOs themselves have broadly
different scopes. Some reviews comment on the implication of the
cost and cost-effectiveness studies for a broad range of jurisdictions,
and others comment on the implication for a much narrower range
(eg, HTA for a single government).
A premise to enable assessment of the synthesis’s adequacy is
a clearly defined objective that includes the intended audience
(jurisdiction or health setting). Guiding questions should be used
to assess clinical, health setting, and methodologic compatibility
(diversity or variability that cannot be measured statistically).
These questions should be informed by tools for assessing trans-
ferability and applicability,53,54 for instance using a decision chart
for assessing the transferability of cost and cost-effectiveness re-
sults between countries.55
Generally, results from modeling studies and empirical studies
should be synthesized separately. Cost and cost-effectiveness
studies based on trials or observational study designs, as well as
probabilistic and deterministic analyses, should be synthesized
separately, too. In addition, incorporating the results of sensitivity
analyses should be considered.56,57
When synthesizing numeric values, articles will likely be
excluded based on missing information necessary for judging
eligibility, applicability, homogeneity, etc. For example, missing
demographic characteristics of the population analyzed may make
it impossible to determine if the study applies to an age group that
the SR-CCEO focuses on. This should be properly documented.
Ideally, sensitivity analysis should be done with and without the
questionable sources.In a SR-CCEO that summarizes cost or cost-effectiveness out-
comes, all cost data should be converted into the same currency. In
addition, it should be expressed in the same year (ie, inflation-
adjusted), using the standard inflator for the country on which
the analysis is focused, before the results are synthesized either
narratively or quantitatively.
In the assessment of costs heterogeneity, the methodologic,
clinical, and setting compatibility should be considered where, in
particular, the latter 2 will have their impact on resource use. For
instance, the choice of conversion approach for costs would
depend on settings’ comparability,53,54 with purchasing power
parity used to compare costs in heterogeneous settings. Although
standardization of costs should be undertaken for the synthesis,
the original costs reported in the study should also be presented in
the SR-CCEO as with all relevant original data, as valuation
methods may differ.58
SR-CCEOs that assess the methodology of included cost
and cost-effectiveness studies have an exceptionally wide set
of methodologic questions on which they may focus.59 Hence,
for such reviews, it is likely that only the broad criteria on
narrative synthesis are applicable, unless the review is based
on a narrow objective of only including studies that are
comparable.
Exploring Heterogeneity in Data
Figure 1 illustrates that the “right” approach for summarizing
cost and cost-effectiveness outcomes depends on the degree of
clinical and methodologic compatibility in the studies included.
When studies are not comparable, narrative synthesis/comparison
will be more appropriate. Although not all of the differences in
reported values can be explained, we strongly encourage the re-
viewers to attempt to do so by analyzing characteristics of the
studies and their impact on outcomes. Some factors, such as
quality of reporting and conflicts of interest in the studies, can be
direct indicators of risks of bias and may contribute to heteroge-
neity in outcomes. It is more challenging, although, to assess how
methodologic differences in the studies contribute to heteroge-
neity in outcomes.
Only in the case where the SR-CCEO’s objective is very
narrowly focused is it feasible to explore associations between
modeling methods and costs or cost-effectiveness outcomes using
meta-regression analysis.60 If methodologic factors that can
potentially explain differences between the studies’ outcomes are
identified, they should be reported.Meta-analysis
Only studies considered compatible with regard to clinical and
health settings (eg, PICO,) and study methodology (ie, time hori-
zon and study perspective) may be considered for synthesis. If a
SR-CCEO pools outcomes in one common metric compatibility of
different health settings (or jurisdictions) should be carefully
assessed (Fig 1). Usually, a very high degree of incompatibility will
imply that pooling such results is not appropriate.
Therefore, a single quantitative synthesis may only be used in
narrowly focused reviews with approaches to synthesis based on a
distribution of outcomes rather than a single “true” outcome (eg,
random-effects models).12,61 A SR-CCEO with a broad scope should
report the results for compatible subgroups that are consciously
selected, ideally based on predefined criteria (eg, results for high-
income Asian countries).
It is the task force’s opinion that the costs reported in various
cost and cost-effectiveness studies are typically (although not al-
ways) more heterogeneous than effects (by heterogeneity we



























































NMB indicates net monetary benefit; WTP, willingness to pay.
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BOX 2. Task Force recommendations to assess publication bias in systematic reviews with cost and cost effectiveness outcomes (SR-
CCEOs)
 Search relevant grey literature (see the grey literature subsection).
 Search for conference proceedings with published abstracts that did not lead to peer-reviewed publications. (Note: Abstracts
should not be searched for inclusion. However, they can be useful to assess possible publication bias.)
 Analyze conflicts of interest (sponsorship) reported in included studies.
 Analyze any differences in studies’ outcomes by sponsorship and publication status (ie, differences between grey literature and
published reports).
 Assess and explore the direction and magnitude of cost and effect differences in publications, for instance, placing the
effectiveness results from cost-effectiveness analyses in the context of existing reviews of clinical effectiveness.
 Analyze the values and interpretations of reported sensitivity analyses (or their lack).
 Benchmark the approaches to exploring the publication bias applied in the clinical reviews, such as looking for the trials’ protocols
and exploring funnel plot asymmetry (if the SR-CCEO includes empirical studies).
BOX 3. Common elements in the existing checklists
assessing cost or cost-effectiveness studies
1. Countries (setting of the study)
2. Population of analysis (population characteristics)
3. Audience and study perspective
4. Time horizon and discounting
5. Adjustment of inflation
6. Interventions compared
7. Method(s) for valuation of cost outcomes
8. Method(s) for valuation of effectiveness and utility
outcomes
9. Compliance/adherence with intervention (eg,
screening uptake)
10. Decision analytic modeling or calculation approach
11. Health outcomes (eg, gained life years, number of
deaths avoided, QALYs)
12. Uncertainty (eg, deterministic and probabilistic
sensitivity analyses, scenario’s, subgroup analyses)
13. Conflicts of interest and sources of funding
14. Software (including open-source software)
QALYs indicates quality of life-years.
ISPOR REPORT 469mean statistically measured variability). Therefore, Figure 1 sug-
gests a hierarchical approach in exploring data compatibility/ho-
mogeneity and pooling the data. This means each next level is
possible on the condition that all of the previous levels have been
achieved. In this way, homogeneity can be assessed in a similar
manner as in clinical reviews.12,61
Data that can be pooled:
 for cost-effectiveness studies, the average and incremental
effectiveness when there is sufficient homogeneity, as well as
clinical and methodologic comparability (the common effec-
tiveness outcomes in cost-effectiveness studies, for example,
quality adjusted life-years [QALYs] or life-years gained),
 for costing studies, the average costs when there is methodo-
logic and health setting comparability,
 for cost-effectiveness studies, the average and incremental costs
when there is methodologic and health setting comparability,
 for cost-effectiveness studies, the net benefit (either net mon-
etary benefit or net health benefit) when homogeneity and
comparability is achieved in all above levels and willingness to
pay threshold homogeneity is observed (or when the dis-
aggregated costs and benefits can be combined using a common
willingness to pay threshold).
To address incomparability among studies, a sensitivity (sub-
group) analysis can be used in a SR-CCEO, similar to the clinical
reviews.
Publication Bias
Publication bias exists if the outcomes of a cost or cost-
effectiveness study influence the publication decision. Bias in
cost-effectiveness studies exists when published incremental
cost-effectiveness ratios (ICERs) cluster around a proposed
threshold, and it is likely to relate to the origin of the sponsor-
ship.47 Publication bias in SR-CCEO can be related to multiple
reasons including:
 failure to submit (sponsored) cost-effectiveness studies that
have unfavorable results (an indicator of publication bias of this
type can be a relationship in study sponsorship and reported
incremental cost-effectiveness of technologies);
 priority setting by target journals publishing cost and cost-
effectiveness studies; for example, preference to publish meth-
odologic research, innovative evaluations (typically conducted
for high-income settings), and to avoid model adaptations.
Assessment of publication bias may not be straightforward in
SR-CCEOs. Researchers are advised to follow the task force’s rec-
ommendations in Box 2. However, none of the proposedassessment methods is perfect and we encourage the develop-
ment of new approaches.Stage 6. Presentation and Reporting
To optimize usefulness, it is important that the review reports,
in sufficient detail, study characteristics and specific outcomes (at
a minimum). More standardized reporting of SR-CCEOs will
improve comparability between reviews and may influence future
reporting in primary studies of cost and cost-effectiveness
analyses.
For SR-CCEOs, the outcomes of interest (eg, total costs, life
years, QALYs), as well as methodologic aspects (eg, study
perspective, health state valuation, type of costs, costs valuation),
should be reported for each included study. Both cost and health
outcomes should be presented separately for each strategy, within
each study. Whether it is relevant to report one “base case” result
or a range of results will depend on each specific research ques-
tion posed in each separate SR-CCEO.39
BOX 4. Developing the ISPOR CiCERO Checklist
The ISPOR CrIteria for Cost (-Effectiveness) Review Outcomes (CiCERO) Checklist is based on the ISPOR Critical Appraisal of
Systematic Reviews with Cost and Cost-Effectiveness Outcomes Good Practices Task Force Report. CiCERO* has a series of
questions to consider when evaluating the risk of bias in reviews reporting cost or cost-effectiveness outcomes or reviews reporting
the methods of these studies.
CiCERO was based on combining aspects of existing instruments, such as the Cochrane Handbook for Systematic Reviews of
Interventions, AMSTAR-2,3 and ROBIS5 plus the deliberation of international experts, task force members representing different
stakeholder perspectives from academics to technology assessors and geographies around the world.†
To produce a final checklist, we used a 2-stage validation approach to improve the readability and inter-rater agreement in use of
the checklist:
(1) By the task force members (8 reviewers, 8 reviews, 2 raters per publication).
(2) By members of the ISPOR student network group (minimum a relevant MSc-level) experienced in assessing cost and cost-
effectiveness outcomes publications and SR-CCEOs (36 reviewers, 27 reviews, 2-4 raters per publication).
The task force members piloted the initial instrument then it was adapted and used by the larger panel of students. Each reviewer
assessed the risk of bias in the reviews independently. The reasons for disagreements were analyzed resulting in amendments that
provided details and clarifications of the checklist. We tested CiCERO on reviews with different objectives: (1) reviews of cost studies,
(2) reviews of cost-effectiveness studies, and (3) reviews that summarize methods of cost and costs-effectiveness studies.
Selection of reviews for validation was based on manuscript diversity in terms of clinical areas, geographical focus, objectives
(methodologic vs synthesis), and outcomes (costs or cost-effectiveness). Comments received from the validation groups and the
disagreement rates for each question were analyzed to optimize understanding and interpretation of the final version of the
checklist.
Finally, the task force report and checklist underwent 3 formal rounds of review to ensure that the good practice recommendations
and checklist meet the high-quality consensus-developed standards of ISPOR Good Practices Task Force Reports.
*There is a shorter version of the CiCERO Checklist for reviews that summarize methods of cost and cost-effectiveness studies and a
specific version for SR-CCEOs that are using AMSTAR-2.
†For more details on task force development, see Appendix A in Supplemental Materials found at https://doi.org/10.1016/j.jval.2021.
01.002 or Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force.
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studies (eg, the characteristics of patient populations and the
methodologic choices adopted in each included study), should
be reported in summary tables. Box 3 presents the common el-
ements in existing checklists assessing methodologic quality or
quality of reporting in cost or cost-effectiveness studies (the
minimum reporting requirements).35,36,38-40 Other elements that
researchers may choose to report will depend on the review’s
objectives, the analyzed interventions, and can, for instance,
include ethical or equity considerations as might have been re-
ported in the studies included, and heterogeneity (subpopula-
tion analysis). The reviewers should acknowledge the process
behind the outcomes of interest choices (eg, whether expert
opinion was involved).
A SR-CCEO that focuses on decision analytic models should
also report the:
 model type and characteristics (eg, clinical pathways, health
states, cycle length, transition possibilities, half-cycle correction
applied);
 model validation (eg, face validity, cross-validation against
other models, internal and external validity);
 components of uncertainty analysis extracted and reported
separately for probabilistic and deterministic sensitivity ana-
lyses, and scenario/subgroup analyses.
In some cases, there will be more aspects that are relevant to
include (eg, disease-specific modeling choices).62
If a SR-CCEO includes studies performed without modeling, the
specific reporting should include study type (eg, RCT or cohort,
method[s] of cost calculation, and eg, regression or descriptive;
questionnaires, expert opinion, and control [or stratification]
variables).A compromise should be found between both the reporting of
outcomes in summary tables and their narrative description, espe-
cially for items of interest. Although aword limit demanded by peer-
reviewed journals can restrict reporting, all the relevant information
that cannot be included in the main paper should be presented in
online appendices, supplementary materials, or study protocols.CiCERO Checklist
Based on the considerations discussed earlier, the task force
developed the ISPOR CiCERO Checklist, a tool to assess the quality
of reporting, conduct, and risk of bias in SR-CCEOs. Using CiCERO
leads to an overview of the quality and risk of bias in an SR-CCEO
(without resulting in a single score). The general conclusion is
dependent on the SR-CCEO’s objectives and the data extracted.
Assessing the quality and risk of bias will identify the review’s
critical weaknesses and give the user a feeling of overall confi-
dence in the results of the SR-CCEO.
CiCERO includes 13 signaling questions to consider when
evaluating the quality of reporting, conduct, and risk of bias in SR-
CCEOs (Appendices C, D, and E for the PDF version and Appendix F
in Supplemental Materials found at https://doi.org/10.1016/j.jval.2
021.01.002 for the Excel version). There are 3 versions of the
CiCERO checklist for: (1) reviews of cost and cost-effectiveness
studies, (2) reviews that summarize methods of cost and costs-
effectiveness studies, and (3) SR-CCEOs that use the AMSTAR-2
instrument to assess quality in included studies.
The process of developing and validating CiCERO is reported in
the Box 4. CiCERO’s development was based on current SR-CCEO
knowledge and experience. Because this is a rapidly developing
research area, it is expected that the task force will update CiCERO
and the report’s recommendations in 5 to 7 years.
ISPOR REPORT 471Limitations of the Task Force Recommendations
and the ISPOR CiCERO Checklist
Although these recommendations were developed to evaluate
the quality of conduct, reporting and risk of bias of SR-CCEOs, they
may be used for conducting a rapid review. A poorly conducted
systematic review, may not perform as well as a properly con-
ducted, transparently reported rapid review.63 So far, limited in-
formation is available on biases related to social networks as a
data source and artificial intelligence in screening and evaluating
the literature. Thus, based on more empirical evidence, these
topics should be detailed in future discussions regarding quality
and risk of bias of SR-CCEO.
Conclusions
As the number of SR-CCEOs continues to increase, standard-
izing the preparation, reporting, and interpretation of their find-
ings is of crucial and growing importance. Such standardization is
required to make effective use of this evidence base to support
healthcare decision-making. This report describes good practice
recommendations, organized in 6 stages, for critically appraising
quality and risk of bias in SR- CCEOs. As such, it provides guidance
to reviewers on how to minimize the risk of bias, as well as
improve the quality of methods and reporting for conducting a SR-
CCEO. In this way, SR-CCEOs can provide valuable evidence to
healthcare decision makers.
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